Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.30 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.30 |
| ▸ | SCN4A | P35499 | 1/20 | 0.30 |
| ▸ | IL1B | P01584 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717697 | 0.90 | KIF11 (0.33) | CSNK1DKCNH2NLRP3PDE2AEPHX1 | |
| SCHEMBL723030 | 0.85 | PDE2A (0.42) | CSNK1DHRH4KCNH2NLRP3PDE2A | |
| SCHEMBL716754 | 0.78 | NPC1 (0.36) | KCNH2MEN1KMT2A | |
| SCHEMBL719872 | 0.76 | PDE2A (0.42) | CSNK1DKCNH2NLRP3PDE2AEPHX1 | |
| SCHEMBL719528 | 0.74 | RCE1 (0.39) | CSNK1DEPHX2 | |
| SCHEMBL14905704 | 0.73 | CSNK1D (0.38) | CSNK1DPDE2AEPHX1MEN1KMT2A | |
| SCHEMBL3095589 | 0.73 | MAPK11 (0.37) | KCNH2PIM1MEN1KMT2AGABBR2 | |
| SCHEMBL14905661 | 0.71 | CSNK1D (0.36) | CSNK1DPDE2AEPHX1MEN1KMT2A | |
| SCHEMBL14493687 | 0.70 | EPHX2 (0.39) | HRH4PDE2AMEN1KMT2AEPHX2 | |
| SCHEMBL17341211 | 0.69 | EPHX2 (0.41) | HRH4MEN1KMT2AEPHX2SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | CSNK1D 3327/4885HRH4 2307/4885KCNH2 2392/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | CSNK1D 3327/4885HRH4 2307/4885KCNH2 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.